Parexel Launches ParexelAI Suite to Accelerate Clinical Trial Operations With Human-Led AI Model
Advertisement
The company said the platform is intended to reduce operational bottlenecks in clinical research by integrating AI tools across site selection, medical writing, regulatory documentation, and pharmacovigilance workflows.
Parexel has launched ParexelAI™, a human-led artificial intelligence suite designed to accelerate clinical trial operations across the drug development lifecycle.
The company said the platform is intended to reduce operational bottlenecks in clinical research by integrating AI tools across site selection, medical writing, regulatory documentation, and pharmacovigilance workflows. ParexelAI is positioned as a “human-in-the-lead” system, combining machine intelligence with oversight from clinical experts.
According to the company, early deployments of the suite have demonstrated a 50% reduction in site selection timelines, a 30% reduction in medical writing workload for Clinical Study Reports, and a 20% reduction in safety literature screening processes.
Parexel also reported regulatory gains through its partnership with Weave Bio, which has helped reduce Investigational New Drug (IND) and New Drug Application (NDA) authoring timelines by up to 60%.
The company’s pharmacovigilance operations have been further strengthened through the acquisition of Vitrana, enabling automation across end-to-end patient safety and compliance workflows.
Parexel said the AI suite is built on a multi-vendor orchestration framework designed to reduce integration complexity across clinical systems. The company also noted that it was the first Contract Research Organization (CRO) to adopt Palantir Technologies’ Artificial Intelligence Platform to support core clinical operations.
The platform also integrates external data networks to improve trial efficiency, including patient identification systems linked to more than 800 research sites and over 2,100 provider locations.
Parexel said the goal of the system is to eliminate repetitive administrative tasks and allow clinical experts to focus on study design, patient safety, and trial execution.
Peyton Howell, Chief Executive Officer of Parexel, said the initiative reflects long-term efforts to embed advanced technology into clinical development processes to improve speed and quality.
The company added that AI is increasingly being used to reduce manual workload in clinical research while maintaining regulatory compliance and data integrity under expert supervision.
Stay tuned for more such updates on Digital Health News
